Bristol Myers Squibb partners with China’s Hengrui Pharma on a dozen drugs The deal, worth up to $15.2 billion, is the latest case of a large pharma company looking to China to expand its pipeline

https://www.statnews.com/2026/05/12/bristol-myers-squibb-hengrui-china-licensing-deal/ By Andrew JosephMay 12, 2026 Europe Correspondent